Compare Godaddy Inc (GDDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Godaddy Inc trades at $92.54 (market cap $12.09B), while Recursion Pharmaceuticals Inc trades at $3.18 (market cap $1.75B). The key difference: Godaddy Inc is far larger — about 6.9× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| GDDY | RXRX | |
|---|---|---|
Market Cap | $12.09B | $1.75B |
Sector | Technology | Health |
52-Week High | $169.40 | $6.79 |
52-Week Low | $75.07 | $2.84 |
Enterprise Value | $14.67B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $91.10, showing modest daily gains. The stock presents a mixed picture: strong technical indicators signal a bullish trend, while fundamentals reveal robust profitability and consistent earnings beats. However, a high P/B ratio and ongoing securities litigation investigations introduce notable risks. The company continues to innovate, recently launching an AI-powered developer platform to expand its service ecosystem.
The outlook is cautiously optimistic. A significant analyst consensus price target of $123 suggests substantial upside potential, supported by strong cash flow and share buybacks. Primary risks include the high valuation on book value, legal overhang from shareholder investigations, and potential revenue growth deceleration. The stock's investment case hinges on execution of its AI initiatives and maintaining its margin profile.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
